Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection

Study:

US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)

Rationale:

n/a

Purpose:

This study is being conducted to assess the safety and tolerability of an oral liquid solution of Sustiva for antiretroviral therapy-naive or therapy-experienced HIV-1 infected children between the ages 3-16 who are failing or intolerant of current antiretroviral regimen and who are unable to swallow Sustiva capsules.

Study Status: No longer available

Recruiting:
n/a

Condition Intervention Phase
HIV Infection Drug: Efavirenz N/A

Verified by Bristol-Myers Squibb January, 2014

Sponsored by: Bristol-Myers Squibb
Information provided by: Bristol-Myers Squibb
ClinicalTrials.gov identifier: NCT00162227

Study Type: Interventional

Study Design: N/A

Cleveland Clinic Florida
Weston, Florida 33331
United States

Bristol-Myers Squibb., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site